78 related articles for article (PubMed ID: 22534670)
1. Use of erlotinib throughout pregnancy: a case-report of a patient with metastatic lung adenocarcinoma.
Rivas G; Llinás N; Bonilla C; Rubiano J; Cuello J; Arango N
Lung Cancer; 2012 Aug; 77(2):469-72. PubMed ID: 22534670
[TBL] [Abstract][Full Text] [Related]
2. A phase II trial of erlotinib as front-line treatment in clinically selected patients with non-small-cell lung cancer.
Pallis AG; Voutsina A; Kentepozidis N; Giassas S; Papakotoulas P; Agelaki S; Tryfonidis K; Kotsakis A; Vamvakas L; Vardakis N; Georgoulias V
Clin Lung Cancer; 2012 Mar; 13(2):129-35. PubMed ID: 22000696
[TBL] [Abstract][Full Text] [Related]
3. Erlotinib administration for advanced non-small cell lung cancer during the first 2 months of unrecognized pregnancy.
Zambelli A; Prada GA; Fregoni V; Ponchio L; Sagrada P; Pavesi L
Lung Cancer; 2008 Jun; 60(3):455-7. PubMed ID: 18063195
[TBL] [Abstract][Full Text] [Related]
4. Good response to gefitinib in lung adenocarcinoma of complex epidermal growth factor receptor (EGFR) mutations with the classical mutation pattern.
Wu SG; Chang YL; Hsu YC; Wu JY; Yang CH; Yu CJ; Tsai MF; Shih JY; Yang PC
Oncologist; 2008 Dec; 13(12):1276-84. PubMed ID: 19060236
[TBL] [Abstract][Full Text] [Related]
5. First-line systemic treatment with gefitinib in stage IV non-small cell lung cancer.
Lange T; Müller-Tidow C; Serve H; Hoffknecht P; Berdel WE; Thomas M
Oncol Rep; 2005 Dec; 14(6):1539-42. PubMed ID: 16273252
[TBL] [Abstract][Full Text] [Related]
6. Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy.
Kim ST; Uhm JE; Lee J; Sun JM; Sohn I; Kim SW; Jung SH; Park YH; Ahn JS; Park K; Ahn MJ
Lung Cancer; 2012 Jan; 75(1):82-8. PubMed ID: 21684626
[TBL] [Abstract][Full Text] [Related]
7. Successful pregnancy with epidermal growth factor receptor tyrosine kinase inhibitor treatment of metastatic lung adenocarcinoma presenting with respiratory failure.
Lee CH; Liam CK; Pang YK; Chua KT; Lim BK; Lai NL
Lung Cancer; 2011 Nov; 74(2):349-51. PubMed ID: 21920622
[TBL] [Abstract][Full Text] [Related]
8. Successful erlotinib rechallenge for leptomeningeal metastases of lung adenocarcinoma after erlotinib-induced interstitial lung disease: a case report and review of the literature.
Togashi Y; Masago K; Hamatani Y; Sakamori Y; Nagai H; Kim YH; Mishima M
Lung Cancer; 2012 Aug; 77(2):464-8. PubMed ID: 22579408
[TBL] [Abstract][Full Text] [Related]
9. Gefitinib-sensitive mutations of the epidermal growth factor receptor tyrosine kinase domain in chinese patients with non-small cell lung cancer.
Mu XL; Li LY; Zhang XT; Wang MZ; Feng RE; Cui QC; Zhou HS; Guo BQ
Clin Cancer Res; 2005 Jun; 11(12):4289-94. PubMed ID: 15958609
[TBL] [Abstract][Full Text] [Related]
10. Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors.
Balak MN; Gong Y; Riely GJ; Somwar R; Li AR; Zakowski MF; Chiang A; Yang G; Ouerfelli O; Kris MG; Ladanyi M; Miller VA; Pao W
Clin Cancer Res; 2006 Nov; 12(21):6494-501. PubMed ID: 17085664
[TBL] [Abstract][Full Text] [Related]
11. Extraordinary response to erlotinib therapy in a patient with lung adenocarcinoma exhibiting KRAS mutation and EGFR amplification.
Krejci J; Pesek M; Grossmann P; Krejci M; Ricar J; Benesova L; Minarik M
Cancer Genomics Proteomics; 2011; 8(3):135-8. PubMed ID: 21518819
[TBL] [Abstract][Full Text] [Related]
12. Erlotinib in lung cancer - molecular and clinical predictors of outcome.
Tsao MS; Sakurada A; Cutz JC; Zhu CQ; Kamel-Reid S; Squire J; Lorimer I; Zhang T; Liu N; Daneshmand M; Marrano P; da Cunha Santos G; Lagarde A; Richardson F; Seymour L; Whitehead M; Ding K; Pater J; Shepherd FA
N Engl J Med; 2005 Jul; 353(2):133-44. PubMed ID: 16014883
[TBL] [Abstract][Full Text] [Related]
13. A multicenter phase II study to evaluate the efficacy and safety of gefitinib as first-line treatment for Korean patients with advanced pulmonary adenocarcinoma harboring EGFR mutations.
Kim DW; Lee SH; Lee JS; Lee MA; Kang JH; Kim SY; Shin SW; Kim HK; Heo DS
Lung Cancer; 2011 Jan; 71(1):65-9. PubMed ID: 20430469
[TBL] [Abstract][Full Text] [Related]
14. Successful rechallenge with erlotinib in a patient with EGFR-mutant lung adenocarcinoma who developed gefitinib-related interstitial lung disease.
Fukui T; Otani S; Hataishi R; Jiang SX; Nishii Y; Igawa S; Mitsufuji H; Kubota M; Katagiri M; Masuda N
Cancer Chemother Pharmacol; 2010 Mar; 65(4):803-6. PubMed ID: 20035424
[TBL] [Abstract][Full Text] [Related]
15. Retreatment with erlotinib: Regain of TKI sensitivity following a drug holiday for patients with NSCLC who initially responded to EGFR-TKI treatment.
Becker A; Crombag L; Heideman DA; Thunnissen FB; van Wijk AW; Postmus PE; Smit EF
Eur J Cancer; 2011 Nov; 47(17):2603-6. PubMed ID: 21784628
[TBL] [Abstract][Full Text] [Related]
16. High efficacy of first-line gefitinib in non-Asian patients with EGFR-mutated lung adenocarcinoma.
Moiseyenko VM; Procenko SA; Levchenko EV; Barchuk AS; Moiseyenko FV; Iyevleva AG; Mitiushkina NV; Togo AV; Semionov II; Ivantsov AO; Matsko DE; Imyanitov EN
Onkologie; 2010; 33(5):231-8. PubMed ID: 20502057
[TBL] [Abstract][Full Text] [Related]
17. CNS response after erlotinib therapy in a patient with metastatic NSCLC with an EGFR mutation.
Pan M; Santamaria M; Wollman DB
Nat Clin Pract Oncol; 2007 Oct; 4(10):603-7. PubMed ID: 17898810
[TBL] [Abstract][Full Text] [Related]
18. Erlotinib response of EGFR-mutant gefitinib-resistant non-small-cell lung cancer.
Chang JW; Chou CL; Huang SF; Wang HM; Hsieh JJ; Hsu T; Cheung YC
Lung Cancer; 2007 Dec; 58(3):414-7. PubMed ID: 17618013
[TBL] [Abstract][Full Text] [Related]
19. A phase II trial of erlotinib in patients with EGFR wild-type advanced non-small-cell lung cancer.
Kobayashi T; Koizumi T; Agatsuma T; Yasuo M; Tsushima K; Kubo K; Eda S; Kuraishi H; Koyama S; Hachiya T; Ohura N
Cancer Chemother Pharmacol; 2012 May; 69(5):1241-6. PubMed ID: 22278730
[TBL] [Abstract][Full Text] [Related]
20. Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients.
Yauch RL; Januario T; Eberhard DA; Cavet G; Zhu W; Fu L; Pham TQ; Soriano R; Stinson J; Seshagiri S; Modrusan Z; Lin CY; O'Neill V; Amler LC
Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8686-98. PubMed ID: 16361555
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
